BioNTech to acquire antibody generation business

German immunotherapeutics specialist BioNTech has reached agreement with fellow Germany-based MAB Discovery to acquire the latter’s operational antibody generation unit.

Under the terms of the accord, BioNTech will acquire all assets, employees and proprietary know-how for monoclonal antibody (MAb) generation from MAB Discovery, while MAB Discovery will retain ownership of and all rights to both its proprietary preclinical development pipeline and its existing third-party service agreements.

Financial terms of the agreement were not disclosed. The acquisition will be completed and the antibody generation unit transitioned at the end of the first quarter of 2019, said BioNTech.